Regulatory · source year

2014 regulatory records

24 selected, source-linked regulatory records dated 2014. This is selective source coverage, not a complete timeline.

Dated records

24 selected records.

Peptide profiles

16 connected profiles.

Cited sources

24 distinct public records.

Cited chronology

Dated source records

All record types in 2014 →

December 2014

2 records

Desmopressin

Federal Register notice 2014-28702

The Federal Register published notice 2014-28702, attributed to FDA and its parent HHS department, on 2014-12-09. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

October 2014

3 records

Leuprolide

Federal Register notice 2014-23961

The Federal Register published notice 2014-23961, attributed to FDA and its parent HHS department, on 2014-10-08. Its official title is “Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

Source: Federal Register via GovInfo ↗

→

September 2014

2 records

August 2014

2 records

Leuprolide

Federal Register notice 2014-19713

The Federal Register published notice 2014-19713, attributed to FDA and its parent HHS department, on 2014-08-20. Its official title is “Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.

Source: Federal Register via GovInfo ↗

→

Liraglutide

Federal Register notice 2014-18304

The Federal Register published notice 2014-18304, attributed to FDA and its parent HHS department, on 2014-08-04. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.

Source: Federal Register via GovInfo ↗

→

July 2014

3 records

Lanreotide

Federal Register notice 2014-17293

The Federal Register published notice 2014-17293, attributed to FDA and its parent HHS department, on 2014-07-23. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide.

Source: Federal Register via GovInfo ↗

→

June 2014

1 record

May 2014

4 records

Linaclotide

Federal Register notice 2014-11926

The Federal Register published notice 2014-11926, attributed to FDA and its parent HHS department, on 2014-05-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; LINZESS,” and PeptideScanner's exact reviewed identity mapping connects the document to Linaclotide.

Source: Federal Register via GovInfo ↗

→

Peginesatide

Federal Register notice 2014-11523

The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.

Source: Federal Register via GovInfo ↗

→

Carfilzomib

Federal Register notice 2014-11175

The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.

Source: Federal Register via GovInfo ↗

→

April 2014

4 records

Icatibant

Federal Register notice 2014-07331

The Federal Register published notice 2014-07331, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.

Source: Federal Register via GovInfo ↗

→

Leuprolide + 1 more

Federal Register notice 2014-07330

The Federal Register published notice 2014-07330, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

Source: Federal Register via GovInfo ↗

→

March 2014

1 record

Oxytocin

Federal Register rule 2014-06131

The Federal Register published rule 2014-06131, attributed to FDA and its parent HHS department, on 2014-03-25. Its official title is “Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.

Source: Federal Register via GovInfo ↗

→

February 2014

2 records

Dalbavancin

Federal Register notice 2014-02942

The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

Source: Federal Register via GovInfo ↗

→